A selective HPLC method for the determination of indapamide in human whole blood: application to a bioequivalence study in Chinese volunteers.
Tai-Jun Hang,Wei Zhao,Jie Liu,Ming Song,Ying Xie,Zhengxing Zhang,Jianping Shen,Yingdi Zhang
DOI: https://doi.org/10.1016/j.jpba.2005.06.035
IF: 3.571
2006-01-01
Journal of Pharmaceutical and Biomedical Analysis
Abstract:Indapamide was extracted from human whole blood with diethyl ether and was determined by a HPLC-UV method using an Inertsil ODS-3 column and an isocratic mobile phase consisting of 55% buffer solution (2g KH2PO4, 3ml H3PO4 and 3.5ml triethylamine in 1l of H2O), 40% acetonitrile and 5% methanol for 12.5min, and then a gradient flush from 100% isocratic to a mixture of 20% isocratic mobile phase and 80% methanol for 3min. Indapamide and glipizide (internal standard) were eluted from the column at about 10.5 and 12.8min, respectively. The method had within day precision values in the range ±1.2 to ±9.7% (n=5) and between day precision in the range ±3.3 to ±9.7%. The method was linear over the range of 10–400ng/ml of indapamide in blood (R=0.999). The LOQ (s/n=10) of the method was 10ng/ml. The method was applied in a study of the pharmacokinetics and bioequivalence of generic indapamide capsules (2.5mg) in comparison with reference indapamide tablets (2.5mg), in 20 healthy male Chinese volunteers. The mean values of major pharmacokinetic parameters of Cmax, AUC0–48, AUC0–∞, Tmax, and t1/2 of indapamide in healthy male Chinese volunteers after po a single 5mg dose for the test product were 331.0±39.2ng/ml, 6193.7±873.5ngh/ml, 7311.8±1232.3ngh/ml, 3.2±0.9h, and 17.3±2.8h, respectively. There was no significant differences between the two formulations.